| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| INCY | Incyte Corporation | $67.04 | $14.25B | N/A |
Incyte Corp. (INCY) Plunged To A New Low After Phase 3 Study Failed
http://www.rttnews.com/story.aspx?Id=2879974
Apr 09, 2018 - Incyte Corp. (INCY) and Merck (MRK) announced Friday morning that their Phase 3 study of Incyte's epacadostat in combination with Merck's KEYTRUDA did not meet the primary endpoint.
0
Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge
http://www.zacks.com/stock/news/298454/incytes-epacadostat-fails-in-melanoma-study-shares-plunge?cid=CS-ZC-FT-298454
Apr 09, 2018 - Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.
0
Incyte's Horrible News Derails a Promising Class of Cancer Drugs
https://www.fool.com/investing/2018/04/06/incytes-horrible-news-derails-a-promising-class-of.aspx?source=iedfolrf0000001
Apr 06, 2018 - The failure of an important trial casts doubt on the future of combination immunotherapy.
0
What Happened in the Stock Market Today
https://www.fool.com/investing/2018/04/06/what-happened-in-the-stock-market-today.aspx?source=iedfolrf0000001
Apr 06, 2018 - On a day stocks plunged, Incyte crashed following a failed drug trial and PriceSmart moved up after reporting rising sales.
0
How a Biotech Bummer Sent Nektar Therapeutics Stock South Today
https://www.fool.com/investing/2018/04/06/how-a-biotech-bummer-sent-nektar-therapeutics-stoc.aspx?source=iedfolrf0000001
Apr 06, 2018 - A high-profile flop for a once-promising cancer drug in development at Incyte is sparking fear across the industry.
0
Why Incyte and NewLink Genetics Crashed Today
https://www.fool.com/investing/2018/04/06/why-incyte-and-newlink-genetics-crashed-today.aspx?source=iedfolrf0000001
Apr 06, 2018 - There's bad news on the clinical trial front.
0
Story Stocks: Incyte falls to two-year lows after melanoma trial does not meet primary endpoints (INCY)
http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=NS20180406110439StoryStocks
Apr 06, 2018 - Incyte (INCY 68.00, -15.07, -18.1%) and Merck (MRK
53.84, -0.68, -1.3%), known as MSD outside the Un
0
INCY: Barclays reits Overweight
http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20180405143748
Apr 05, 2018 - Barclays issues rating change for INCY
0
Are Short-Sellers Right About Geron Corporation?
https://www.fool.com/investing/2018/04/02/are-short-sellers-right-about-geron-corporation.aspx?source=iedfolrf0000001
Apr 02, 2018 - The short argument against Geron doesn't add up. Here's why.
0
3 Biotechs That Could Get Big Boosts in April
https://www.fool.com/investing/2018/03/28/3-biotechs-that-could-get-big-boosts-in-april.aspx?source=iedfolrf0000001
Mar 28, 2018 - April showers might bring May flowers. But they also bring major FDA decisions for these biotechs.
0